Effect of Cymbopogon citratus on contact dermatitis

Formulation and physicochemical characterization of the topical preparation from Cymbopogon citratus (DC.) Stapf. and its effect on contact dermatitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190425043372N1

Enrollment

Registered

2020-02-06

Start date

2019-12-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contact dermatitis. Irritant contact dermatitis

Interventions

Intervention 1: Intervention group: topical cream containing Cymbopogon citratus oil with paraffin base formulated in tehran university of medical science Iranian medicine faculty ,consumption instruc

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients older than 18 years old Patients who suffers from mild to moderate contact dermatitis according to EASI index

Exclusion criteria

Exclusion criteria: Patients who have used oral corticosteroides, 2 months before study Patients who have used topical immunosuppressants 4 weeks before study Pregnant women Breastfeeding women Patients who have contact dermatitis history to herbal formulations Patients who have skin infections Patients who have immunosuppressive diseases

Design outcomes

Primary

Measure	Time frame
Eczema score according to EASI. Timepoint: Measuring EASI index at first day of study (before using topical formulation), 28 and 56 days after using formulation. Method of measurement: Eczema Area and Severity Index (EASI).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodeh Karami

Tehran University of Medical Sciences

s-karami@razi.tums.ac.ir+98 21 4683 0133

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026